NeoPharm (Korea) Performance
| 092730 Stock | KRW 11,950 10.00 0.08% |
NeoPharm has a performance score of 4 on a scale of 0 to 100. The company secures a Beta (Market Risk) of -0.38, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning NeoPharm are expected to decrease at a much lower rate. During the bear market, NeoPharm is likely to outperform the market. NeoPharm LTD right now secures a risk of 2.88%. Please verify NeoPharm LTD downside deviation, standard deviation, total risk alpha, as well as the relationship between the coefficient of variation and jensen alpha , to decide if NeoPharm LTD will be following its current price movements.
Risk-Adjusted Performance
4 of 100
Weak | Strong |
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in NeoPharm LTD are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, NeoPharm may actually be approaching a critical reversion point that can send shares even higher in January 2025. ...more
| Total Cashflows From Investing Activities | -16.7 B |
NeoPharm |
NeoPharm Relative Risk vs. Return Landscape
If you would invest 1,120,000 in NeoPharm LTD on September 15, 2024 and sell it today you would earn a total of 75,000 from holding NeoPharm LTD or generate 6.7% return on investment over 90 days. NeoPharm LTD is generating 0.1505% of daily returns and assumes 2.8836% volatility on return distribution over the 90 days horizon. Simply put, 25% of stocks are less volatile than NeoPharm, and 97% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
NeoPharm Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for NeoPharm's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as NeoPharm LTD, and traders can use it to determine the average amount a NeoPharm's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0522
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | 092730 | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.88 actual daily | 25 75% of assets are more volatile |
Expected Return
| 0.15 actual daily | 2 98% of assets have higher returns |
Risk-Adjusted Return
| 0.05 actual daily | 4 96% of assets perform better |
Based on monthly moving average NeoPharm is performing at about 4% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of NeoPharm by adding it to a well-diversified portfolio.
NeoPharm Fundamentals Growth
NeoPharm Stock prices reflect investors' perceptions of the future prospects and financial health of NeoPharm, and NeoPharm fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on NeoPharm Stock performance.
| Return On Equity | 13.82 | |||
| Return On Asset | 0.11 | |||
| Profit Margin | 0.21 % | |||
| Operating Margin | 0.26 % | |||
| Current Valuation | 153.58 B | |||
| Shares Outstanding | 7.99 M | |||
| Price To Earning | 42.54 X | |||
| Price To Sales | 1.56 X | |||
| Revenue | 87.93 B | |||
| EBITDA | 24.3 B | |||
| Cash And Equivalents | 7.05 B | |||
| Total Debt | 101.79 M | |||
| Debt To Equity | 0.60 % | |||
| Book Value Per Share | 4,777 X | |||
| Cash Flow From Operations | 21.68 B | |||
| Earnings Per Share | 576.00 X | |||
| Total Asset | 143.41 B | |||
| Retained Earnings | 19.71 B | |||
| Current Asset | 22.83 B | |||
| Current Liabilities | 6.06 B | |||
About NeoPharm Performance
By analyzing NeoPharm's fundamental ratios, stakeholders can gain valuable insights into NeoPharm's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if NeoPharm has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if NeoPharm has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
,Ltd. manufactures and sells skin care products in Korea and internationally. ,Ltd. was founded in 2000 and is headquartered in Daejeon, South Korea. Neopharm is traded on Korean Securities Dealers Automated Quotations in South Korea.Things to note about NeoPharm LTD performance evaluation
Checking the ongoing alerts about NeoPharm for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for NeoPharm LTD help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| About 39.0% of the company shares are owned by insiders or employees |
- Analyzing NeoPharm's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether NeoPharm's stock is overvalued or undervalued compared to its peers.
- Examining NeoPharm's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating NeoPharm's management team can have a significant impact on its success or failure. Reviewing the track record and experience of NeoPharm's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of NeoPharm's stock. These opinions can provide insight into NeoPharm's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for NeoPharm Stock analysis
When running NeoPharm's price analysis, check to measure NeoPharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NeoPharm is operating at the current time. Most of NeoPharm's value examination focuses on studying past and present price action to predict the probability of NeoPharm's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NeoPharm's price. Additionally, you may evaluate how the addition of NeoPharm to your portfolios can decrease your overall portfolio volatility.
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Equity Valuation Check real value of public entities based on technical and fundamental data |